A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+ Breast Cancer
Triple Negative Breast Cancer (TNBC)
CCNE1 Amplified Advanced Solid Tumors
HR+ HER2- Breast Cancer
Ovarian Cancer
Endometrial Cancer
Uterine Carcinosarcoma

Interventions

DRUG: NKT5097 CDK2/CDK4 dual degrader

Sponsor

NiKang Therapeutics, Inc.